Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
2023年12月14日 - 9:30PM
Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage
clinical biotechnology company developing transformative medicines
to dramatically improve the lives of patients with life-altering
immune and inflammatory diseases, announced today that Clay
Siegall, PhD, has been appointed as Chairman of the Board.
“We are absolutely thrilled that Clay has joined
Tourmaline as Chairman of the Board,” said Sandeep Kulkarni, MD,
Co-Founder and Chief Executive Officer of Tourmaline. “Clay built
Seagen into one of the largest independent biotech companies in the
world by taking a therapeutic concept and developing from it
multiple successful medicines for cancer patients. He is a standout
entrepreneur and a seasoned operating executive. Adding Clay’s
demonstrated leadership to our team strengthens our ability to
deliver transformative medicines for patients and positions
Tourmaline well for many important milestones ahead.”
Dr. Siegall is currently President, Chief
Executive Officer, and Chairman of the Board of Immunone, Inc., a
biotechnology company focused on developing first-in-class and
best-in-class targeted cancer therapies. He previously served as
the CEO and President of Seagen, Inc., which he co-founded in July
1997. Under his 25 years of leadership, Seagen became the world
leader in antibody-drug conjugate (ADC) therapeutics, earned FDA
approvals for four cancer therapies, and grew to over $2 billion in
annual revenue. During his tenure, he raised well over $1 billion
in financing for Seagen from public and private market investors
and oversaw the company’s successful acquisition of Cascadian
Therapeutics. Pfizer, Inc. expects to close its purchase of Seagen
for $43 billion in December 2023. Prior to Seagen, Dr. Siegall
worked in positions of increasing responsibilities at Bristol Myers
Squibb and at the National Cancer Institute. He received a PhD in
Genetics from George Washington University and a BS in Zoology from
the University of Maryland.
“I am honored to be joining the Tourmaline team
in the pursuit of transformative medicines for immune and
inflammatory diseases,” said Dr. Siegall. “Tourmaline has the right
inputs to become a great company: a de-risked development plan
guided by clinical evidence, an impressive board spanning many
disciplines, and passionate leadership. The company’s lead asset,
TOUR006, has best-in-class potential to address the unmet needs of
large numbers of patients across many indications. I look forward
to working with Sandeep, the Board of Directors, and the rest of
the management team to build a highly valuable organization.”
About Tourmaline Bio, Inc.
Tourmaline Bio is a late-stage clinical
biotechnology company driven by its mission to develop
transformative medicines that dramatically improve the lives of
patients. Tourmaline is currently developing TOUR006 for the
treatment of life-altering immune and inflammatory diseases.
About TOUR006
TOUR006 is a long-acting, fully human, anti-IL-6
monoclonal antibody with best-in-class potential, having
differentiated properties, including high binding affinity to IL-6
and a substantially long half-life of approximately 7 weeks. To
date, TOUR006 has been studied in 448 patients including those with
autoimmune disorders, across six clinical trials. Tourmaline is
developing TOUR006 in Thyroid Eye Disease (TED) and atherosclerotic
cardiovascular disease (ASCVD) as its first two indications, with
additional diseases under consideration.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, including but
not limited to, express or implied statements regarding
Tourmaline’s clinical development activities, including with
respect to TOUR006 and the potential benefits that may be realized
as a result of the appointment of Dr. Siegall. All statements other
than statements of historical fact contained in this press release
are forward-looking statements.
Forward-looking statements are subject to a
number of risks and uncertainties, many of which involve factors or
circumstances that are beyond Tourmaline’s control. Tourmaline’s
actual results could differ materially from those stated or implied
in forward-looking statements due to a number of factors,
including, but not limited to, (i) the inherent risks and
uncertainties associated with the clinical development of product
candidates, including potential delays in the commencement,
enrollment and completion of clinical trials and unexpected safety
or efficacy data observed during clinical studies; (ii) the
uncertainties and timing of the regulatory approval process for
Tourmaline’s product candidates, as well as changes in the
regulatory environment; (iii) changes in expected or existing
competition; (iv) the sufficiency of Tourmaline’s capital and other
resources; and (v) unexpected litigation or other disputes. These
and other risks and uncertainties are more fully described in
Tourmaline’s filings with the Securities and Exchange Commission,
including the “Risk Factors” contained therein. These
forward-looking statements are made as of the date they were first
issued, and were based on the then-current expectations, estimates,
forecasts, and projections, as well as the beliefs and assumptions
of management. There can be no assurance that future developments
affecting Tourmaline will be those that have been anticipated.
Except as may be required under applicable law, Tourmaline
expressly disclaims any obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
Investor Contact
Lee M. SternMeru Advisorslstern@meruadvisors.com
Tourmaline Bio (NASDAQ:TRML)
過去 株価チャート
から 8 2024 まで 9 2024
Tourmaline Bio (NASDAQ:TRML)
過去 株価チャート
から 9 2023 まで 9 2024